The US Supreme Court declined to review a drugmaker’s lawsuit against a rival regarding the sale of unapproved compounded prescription drugs and state unfair-competition laws.
The nation’s highest court rejected Hope Medical Enterprises Inc.’s petition to review a suit against Fagron Compounding LLC alleging that Fagron’s sales of compounded drugs that lack approval from the Food and Drug Administration are unfair and unlawful, violating several states’ consumer protection laws.
The US Court of Appeals for the Ninth Circuit in July 2023 sided with Fagron, reversing a district court ruling in favor of Hope Medical. The three-judge panel’s opinion cited the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.